235 related articles for article (PubMed ID: 33782384)
41. Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-β1/smad2/3 axis in pancreatic cancer.
Zhang B; Ye H; Ren X; Zheng S; Zhou Q; Chen C; Lin Q; Li G; Wei L; Fu Z; Zhang Y; Hu C; Li Z; Chen R
Cancer Lett; 2019 Sep; 459():204-215. PubMed ID: 31199988
[TBL] [Abstract][Full Text] [Related]
42. TGF-β1 secreted by pancreatic stellate cells promotes stemness and tumourigenicity in pancreatic cancer cells through L1CAM downregulation.
Cave DD; Di Guida M; Costa V; Sevillano M; Ferrante L; Heeschen C; Corona M; Cucciardi A; Lonardo E
Oncogene; 2020 May; 39(21):4271-4285. PubMed ID: 32291413
[TBL] [Abstract][Full Text] [Related]
43. ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage.
Chakraborty A; Dorsett KA; Trummell HQ; Yang ES; Oliver PG; Bonner JA; Buchsbaum DJ; Bellis SL
J Biol Chem; 2018 Jan; 293(3):984-994. PubMed ID: 29191829
[TBL] [Abstract][Full Text] [Related]
44. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
[TBL] [Abstract][Full Text] [Related]
45. DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine.
Liu F; Gore AJ; Wilson JL; Korc M
PLoS One; 2014; 9(1):e84982. PubMed ID: 24409315
[TBL] [Abstract][Full Text] [Related]
46. Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.
Sumiyoshi H; Matsushita A; Nakamura Y; Matsuda Y; Ishiwata T; Naito Z; Uchida E
Oncol Rep; 2016 Jun; 35(6):3216-26. PubMed ID: 27035235
[TBL] [Abstract][Full Text] [Related]
47. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
48. Vactosertib, TGF-β receptor I inhibitor, augments the sensitization of the anti-cancer activity of gemcitabine in pancreatic cancer.
Lee JE; Lee P; Yoon YC; Han BS; Ko S; Park MS; Lee YJ; Kim SE; Cho YJ; Lim JH; Ryu JK; Shim S; Kim DK; Jung KH; Hong SS
Biomed Pharmacother; 2023 Jun; 162():114716. PubMed ID: 37086509
[TBL] [Abstract][Full Text] [Related]
49. The antioxidant transcription factor Nrf2 modulates the stress response and phenotype of malignant as well as premalignant pancreatic ductal epithelial cells by inducing expression of the ATF3 splicing variant ΔZip2.
Kha ML; Hesse L; Deisinger F; Sipos B; Röcken C; Arlt A; Sebens S; Helm O; Schäfer H
Oncogene; 2019 Feb; 38(9):1461-1476. PubMed ID: 30302023
[TBL] [Abstract][Full Text] [Related]
50. Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer.
Qian W; Li J; Chen K; Jiang Z; Cheng L; Zhou C; Yan B; Cao J; Ma Q; Duan W
Life Sci; 2018 Sep; 208():253-261. PubMed ID: 30053447
[TBL] [Abstract][Full Text] [Related]
51. Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells.
Lu C; Yang D; Sabbatini ME; Colby AH; Grinstaff MW; Oberlies NH; Pearce C; Liu K
BMC Cancer; 2018 Feb; 18(1):149. PubMed ID: 29409480
[TBL] [Abstract][Full Text] [Related]
52. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
[TBL] [Abstract][Full Text] [Related]
53. The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells.
Cioffi M; Trabulo SM; Sanchez-Ripoll Y; Miranda-Lorenzo I; Lonardo E; Dorado J; Reis Vieira C; Ramirez JC; Hidalgo M; Aicher A; Hahn S; Sainz B; Heeschen C
Gut; 2015 Dec; 64(12):1936-48. PubMed ID: 25887381
[TBL] [Abstract][Full Text] [Related]
54. Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer.
Asuthkar S; Stepanova V; Lebedeva T; Holterman AL; Estes N; Cines DB; Rao JS; Gondi CS
Mol Biol Cell; 2013 Sep; 24(17):2620-32. PubMed ID: 23864708
[TBL] [Abstract][Full Text] [Related]
55. The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma.
Panzeri V; Manni I; Capone A; Naro C; Sacconi A; Di Agostino S; de Latouliere L; Montori A; Pilozzi E; Piaggio G; Capurso G; Sette C
Mol Oncol; 2021 Feb; 15(2):579-595. PubMed ID: 33159833
[TBL] [Abstract][Full Text] [Related]
56. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells.
Calabretta S; Bielli P; Passacantilli I; Pilozzi E; Fendrich V; Capurso G; Fave GD; Sette C
Oncogene; 2016 Apr; 35(16):2031-9. PubMed ID: 26234680
[TBL] [Abstract][Full Text] [Related]
57. FZD7 accelerates hepatic metastases in pancreatic cancer by strengthening EMT and stemness associated with TGF-β/SMAD3 signaling.
Zhang Z; Xu Y
Mol Med; 2022 Jul; 28(1):82. PubMed ID: 35854234
[TBL] [Abstract][Full Text] [Related]
58. FGF2 engineered SPIONs attenuate tumor stroma and potentiate the effect of chemotherapy in 3D heterospheroidal model of pancreatic tumor.
Mardhian DF; Vrynas A; Storm G; Bansal R; Prakash J
Nanotheranostics; 2020; 4(1):26-39. PubMed ID: 31911892
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
[TBL] [Abstract][Full Text] [Related]
60. RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma.
Tu Q; Liu X; Yao X; Li R; Liu G; Jiang H; Li K; Chen Q; Huang X; Chang Q; Xu G; Zhu H; Shi P; Zhao B
J Exp Clin Cancer Res; 2022 Sep; 41(1):274. PubMed ID: 36109793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
